Protective efficacy in mice of monovalent and trivalent live attenuated influenza vaccines in the background of cold-adapted A/X-31 and B/Lee/40 donor strains

Vaccine

Volumn 32, Issue 5, 2014, Pages 535-543

  Jang, Yo Han ^a   Lee, Eun Young ^a,b   Byun, Young Ho ^a   Jung, Eun Ju ^a,c   Lee, Yoon Jae ^a   Lee, Yun Ha ^a   Lee, Kwang Hee ^a   Lee, Jinhee ^a   Seong, Baik Lin ^a  

^a Yonsei University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c The Catholic University ^*  (South Korea)

Author keywords

A X 31 ca; B Lee 40 ca; Influenza virus; Mouse study; Seasonal influenza vaccine; Trivalent vaccine

Indexed keywords

COLD ADAPTED LIVE ATTENUATED INFLUENZA VACCINE; INFLUENZA VACCINE; TRIPLE VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENETIC REASSORTMENT; HEMAGGLUTINATION INHIBITION TEST; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA A; INFLUENZA B; INFLUENZA VIRUS A; INFLUENZA VIRUS B; LUNG HOMOGENATE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; VACCINATION; VIRUS ATTENUATION; VIRUS CULTURE; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS TITRATION; WEIGHT CHANGE; WEIGHT REDUCTION;

A/X-31 CA; B/LEE/40 CA; INFLUENZA VIRUS; MOUSE STUDY; SEASONAL INFLUENZA VACCINE; TRIVALENT VACCINE;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS; REASSORTANT VIRUSES; VACCINES, ATTENUATED;

EID: 84891662613     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.12.002     Document Type: Article

References (39)

1. Nicholson K.G., Wood J.M., Zambon M. Influenza. Lancet 2003, 362:1733-1745.
2. Potter C.W. A history of influenza. J Appl Microbiol 2001, 91:572-579.
3. Shaw A. New technologies for new influenza vaccines. Vaccine 2012, 30:4927-4933.
4. Nichol K.L., Treanor J.J. Vaccines for seasonal and pandemic influenza. J Infect Dis 2006, 194:S111-S118.
5. Belshe R.B. Current status of live attenuated influenza virus vaccine in the US. Virus Res 2004, 103:177-185.
6. Jang Y.H., Seong B-L. Principles underlying rational design of live attenuated influenza vaccines. Clin Exp Vaccine Res 2012, 1:35-49.
7. Jang Y.H., Seong B.L. Cross-protective immune responses elicited by live attenuated influenza vaccines. Yonsei Med J 2013, 54:271-282.
8. Ghendon Y.Z., Polezhaev F.I., Lisovskaya K.V., Medvedeva T.E., Alexandrova G.I., Klimov A.I. Recombinant cold-adapted attenuated influenza A vaccines for use in children: molecular genetic analysis of the cold-adapted donor and recombinants. Infect Immun 1984, 44:730-733.
9. Ghendon Y.Z., Klimov A.I., Alexandrova G.I., Polezhaev F.I. Analysis of genome composition and reactogenicity of recombinants of cold-adapted and virulent virus strains. J Gen Virol 1981, 53:215-224.
10. Maassab H.F., DeBorde D.C. Development and characterization of cold-adapted viruses for use as live virus vaccines. Vaccine 1985, 3:355-369.
11. Kiseleva I.V., Voeten J.T.M., Teley L.C.P., Larionova N.V., Drieszen-van der Cruijsen S.K.M., Basten S.M.C., et al. PB2 and PA genes control the expression of the temperature-sensitive phenotype of cold-adapted B/USSR/60/69 influenza master donor virus. J Gene Virol 2010, 91:931-937.
12. Voeten J.T., Kiseleva I.V., Glansbeek H.L., Basten S.M., Drieszen-van der Cruijsen S.K., Rudenko L.G., et al. Master donor viruses A/Leningrad/134/17/57 (H2N2) and B/USSR/60/69 and derived reassortants used in live attenuated influenza vaccine (LAIV) do not display neurovirulent properties in a mouse model. Arch Virol 2010, 155:1391-1399.
13. Lee K.H., Seo S.U., Song J.M., Lee C.M., Kim H.A., Seong B.L. Characterization of live influenza vaccine donor strain derived from cold-adaptation of X-31 virus. Vaccine 2006, 24:1966-1974.
14. Seo S.U., Byun Y.H., Lee E.Y., Jung E.J., Jang Y.H., Kim H.A., et al. Development and characterization of a live attenuated influenza B virus vaccine candidate. Vaccine 2008, 26:874-881.
15. Jang Y.H., Byun Y.H., Lee D.H., Lee K.H., Lee Y.J., Lee Y.H., et al. Cold-adapted X-31 live attenuated 2009 pandemic H1N1 influenza vaccine elicits protective immune responses in mice and ferrets. Vaccine 2013, 31:1320-1327.
16. Jang Y.H., Byun Y.H., Lee Y.J., Lee Y.H., Lee K.H., Seong B.L. Cold-adapted pandemic 2009 H1N1 influenza virus live vaccine elicits cross-reactive immune responses against seasonal and H5 influenza A viruses. J Virol 2012, 86:5953-5958.
17. Jang Y.H., Jung E.J., Byun Y.H., Lee K.H., Lee E.Y., Lee Y.J., et al. Immunogenicity and protective efficacy of cold-adapted X-31 live attenuated pre-pandemic H5N1 influenza vaccines. Vaccine 2013.
18. Glezen W.P. Cold-adapted, live attenuated influenza vaccine. Expert Rev Vaccines 2004, 3:131-139.
19. Pfleiderer M., Lower J., Kurth R. Cold-attenuated live influenza vaccines, a risk-benefit assessment. Vaccine 2001, 20:886-894.
20. Belshe R., Lee M.S., Walker R.E., Stoddard J., Mendelman P.M. Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev Vaccines 2004, 3:643-654.
21. Wareing M.D., Watson J.M., Brooks M.J., Tannock G.A. Immunogenic and isotype-specific responses to Russian and US cold-adapted influenza a vaccine donor strains A/Leningrad/134/17/57, A/Leningrad/134/47/57, and A/Ann Arbor/6/60 (H2N2) in mice. J Med Virol 2001, 65:171-177.
22. + cytokine responses in mice reveal differences in the relative immunogenicity of cold-adapted influenza A vaccine donor strains. Vaccine 2005, 23:4075-4081.
23. Alexandrova G.I., Maassab H.F., Kendal A.P., Medvedeva T.E., Egorov A.Y., Klimov A.I., et al. Laboratory properties of cold-adapted influenza B live vaccine strains developed in the US and USSR, and their B/Ann Arbor/1/86 cold-adapted reassortant vaccine candidates. Vaccine 1990, 8:61-64.
24. Ha S.H., Kim H.A., Kim Y.H., Kim J.S., Lee K.H., Park S.Y., et al. A multiplex RT-PCR method for screening of reassortant live influenza vaccine virus strains. J Virol Methods 2006, 134:154-163.
25. Pica N., Iyer A., Ramos I., Bouvier N.M., Fernandez-Sesma A., Garcia-Sastre A., et al. The DBA.2 mouse is susceptible to disease following infection with a broad, but limited, range of influenza A and B viruses. J Virol 2011, 85:12825-12829.
26. Murphy B.R., Coelingh K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol 2002, 15:295-323.
27. Gruber W.C., Belshe R.B., King J.C., Treanor J.J., Piedra P.A., Wright P.F., et al. Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza Vaccine Investigators Group. J Infect Dis 1996, 173:1313-1319.
28. Gruber W.C., Campbell P.W., Thompson J.M., Reed G.W., Roberts B., Wright P.F. Comparison of live attenuated and inactivated influenza vaccines in cystic fibrosis patients and their families: results of a 3-year study. J Infect Dis 1994, 169:241-247.
29. Gruber W.C., Kirschner K., Tollefson S., Thompson J., Reed G., Edwards K.M., et al. Comparison of monovalent and trivalent live attenuated influenza vaccines in young children. J Infect Dis 1993, 168:53-60.
30. Bandell A., Woo J., Coelingh K. Protective efficacy of live-attenuated influenza vaccine (multivalent, Ann Arbor strain): a literature review addressing interference. Expert Rev Vaccines 2011, 10:1131-1141.
31. ®-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly. Vaccine 2012, 30:1388-1396.
32. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. New Engl J Med 2006, 354:1343-1351.
33. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007, 370:580-589.
34. Tannock G.A., Paul J.A., Barry R.D. Relative immunogenicity of the cold-adapted influenza virus A/Ann Arbor/6/60 (A/AA/6/60-ca), recombinants of A/AA/6/60-ca, and parental strains with similar surface antigens. Infect Immun 1984, 43:457-462.
35. Atmar R.L., Keitel W.A., Cate T.R., Quarles J.M., Couch R.B. Comparison of trivalent cold-adapted recombinant (CR) influenza virus vaccine with monovalent CR vaccines in healthy unselected adults. J Infect Dis 1995, 172:253-257.
36. Keitel W.A., Couch R.B., Quarles J.M., Cate T.R., Baxter B., Maassab H.F. Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults. J Infect Dis 1993, 167:305-311.
37. Potter C.W., Jennings R., Clark A., Ali M. Interference following dual inoculation with influenza A (H3N2) and (H1N1) viruses in ferrets and volunteers. J Med Virol 1983, 11:77-86.
38. Belshe R.B., Coelingh K., Ambrose C.S., Woo J.C., Wu X. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 2010, 28:2149-2156.
39. Uyeki T.M., Cox N.J. Global concerns regarding novel influenza A (H7N9) virus infections. New Engl J Med 2013, 368:1862-1864.